Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Phase 1
Terminated
Conditions
Breast Cancer
Cancer
Interventions
Drug: Venetoclax
Drug: Capecitabine
First Posted Date
2020-02-18
Last Posted Date
2020-10-29
Lead Sponsor
AbbVie
Target Recruit Count
4
Registration Number
NCT04274933
Locations
🇺🇸

Greenville Health System Cance /ID# 216059, Greenville, South Carolina, United States

🇩🇪

Universitaetsklinik Heidelberg /ID# 214679, Heidelberg, Baden-Wuerttemberg, Germany

🇵🇷

GCM Medical Group PSC - Hato Rey /ID# 216904, San Juan, Puerto Rico

and more 15 locations

Ibrutinib + Venetoclax in Untreated WM

First Posted Date
2020-02-17
Last Posted Date
2024-04-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
45
Registration Number
NCT04273139
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

First Posted Date
2020-02-17
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
247
Registration Number
NCT04269902
Locations
🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States

🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 610 locations

Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

Phase 2
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Venetoclax
First Posted Date
2020-02-12
Last Posted Date
2022-12-14
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
104
Registration Number
NCT04267081
Locations
🇫🇮

HelsinkiUCH, Helsinki, Uusimaa, Finland

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

First Posted Date
2020-02-12
Last Posted Date
2024-12-17
Lead Sponsor
Takeda
Target Recruit Count
164
Registration Number
NCT04266795
Locations
🇺🇸

Houston Methodist Cancer Center, Houston, Texas, United States

🇺🇸

UC Irvine Medical Center, Orange, California, United States

🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 54 locations

Acute Myeloid Leukemia Real World Treatment Patterns

First Posted Date
2020-01-18
Last Posted Date
2023-06-07
Lead Sponsor
Pfizer
Registration Number
NCT04230564

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

First Posted Date
2020-01-18
Last Posted Date
2024-04-09
Lead Sponsor
Sellas Life Sciences Group
Target Recruit Count
128
Registration Number
NCT04229979
Locations
🇺🇸

Mayo Clinic Jacksonville Florida, Jacksonville, Florida, United States

🇫🇷

CHU de Caen, Caen, France

🇬🇷

General Hospital of Athens "Evaggelismos", Athens, Greece

and more 70 locations

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

First Posted Date
2020-01-02
Last Posted Date
2024-07-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT04216524
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

First Posted Date
2020-01-02
Last Posted Date
2022-01-19
Lead Sponsor
Aprea Therapeutics
Target Recruit Count
51
Registration Number
NCT04214860
Locations
🇺🇸

Northwestern Medicine, Chicago, Illinois, United States

🇺🇸

H. Lee Moffitt CC, Tampa, Florida, United States

🇺🇸

Weill Cornell Cancer Center, New York, New York, United States

and more 5 locations

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

First Posted Date
2019-12-05
Last Posted Date
2024-11-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT04188405
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy